Uncategorized
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
G1 Therapeutics to Lay Off Staff After Cosela Fails in Pivotal Breast Cancer Study
G1 Therapeutics, Cosela, Breast Cancer, Layoffs, Phase 3 Trial, Trilaciclib, Metastatic Triple Negative Breast Cancer
Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran
Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply
Lilly’s Zepbound Shows Promise in Resolving Sleep Apnea in Obese Patients, Strengthening Case for Label Expansion
Zepbound, tirzepatide, sleep apnea, obesity, label expansion, Eli Lilly, SURMOUNT-OSA program, weight loss, FDA approval
Argenx’s Vyvgart Hytrulo Secures Second US Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder
FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer
Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras
Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval
Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals
Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap
Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome
Fractyl Highlights GLP-1 Gene Therapy Potential, Delays Clinical Trials to 2025
Fractyl, GLP-1 gene therapy, clinical trials, diabetes, ADA24